Literature DB >> 2156082

Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.

O A Alvarez1, D F Carmichael, Y A DeClerck.   

Abstract

Metalloproteinases secreted by tumor cells play an important role in metastasis. In the present study, we determined whether an inhibitor of these proteinases could inhibit the ability of tumor cells to degrade collagen and to metastasize. Metalloproteinases with degradative activities for type I collagen, type IV collagen, gelatin, and casein were secreted by a highly metastatic rat embryo cell line (4R) transfected by c-Ha-ras1 (also known as HRAS1). These metalloproteinases were identified by sodium dodecyl sulfate substrate-polyacrylamide gel electrophoresis as 92-kilodalton and 68-kilodalton gelatinolytic enzymes and 48-kilodalton and 45-kilodalton caseinolytic proteinases. A recombinant human tissue inhibitor of metalloproteinases (rTIMP) completely inhibited the proteolytic activities of these enzymes and was also a potent inhibitor of the proteolytic degradation of collagen by intact c-Ha-ras1-transfected cells. The ability of these cells to colonize the lungs after intravenous injection into nude mice was inhibited by 83% when rTIMP was repeatedly injected intraperitoneally into the animals. These data demonstrate that rTIMP is a potent inhibitor of the metalloproteinase activities of these cells and can also inhibit their metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156082     DOI: 10.1093/jnci/82.7.589

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  53 in total

Review 1.  The role of cellular proteases and their inhibitors in invasion and metastasis. Introductionary overview.

Authors:  L Liotta
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

2.  Gene expression signatures of site-specificity in cancer metastases.

Authors:  Franz Hartung; Aditya Patil; Rohan J Meshram; Georg F Weber
Journal:  Clin Exp Metastasis       Date:  2019-09-25       Impact factor: 5.150

3.  Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10.

Authors:  S Wagner; C Stegen; H Bouterfa; C Huettner; S Kerkau; W Roggendorf; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 4.  The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction.

Authors:  R Khokha; P Waterhouse
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 6.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

Review 8.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; S B Gruber; R J Muschel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 10.  The role of endothelial cells in tumor invasion and metastasis.

Authors:  N Jahroudi; J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.